Guardant Health, Inc. (NASDAQ:GH) Holdings Lifted by Blue Water Life Science Advisors LP

Blue Water Life Science Advisors LP lifted its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 53.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 694,047 shares of the company's stock after purchasing an additional 243,000 shares during the quarter. Guardant Health comprises 18.8% of Blue Water Life Science Advisors LP's investment portfolio, making the stock its 2nd biggest holding. Blue Water Life Science Advisors LP owned about 0.56% of Guardant Health worth $21,203,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Guardant Health by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock worth $368,205,000 after purchasing an additional 350,606 shares in the last quarter. Geode Capital Management LLC grew its position in Guardant Health by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock worth $64,754,000 after purchasing an additional 29,686 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in Guardant Health by 19.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after purchasing an additional 238,037 shares in the last quarter. Nikko Asset Management Americas Inc. increased its stake in Guardant Health by 15.6% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after buying an additional 197,729 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Guardant Health during the 4th quarter worth approximately $36,438,000. 92.60% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

GH has been the subject of a number of research analyst reports. Barclays decreased their price target on Guardant Health from $60.00 to $55.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. Mizuho began coverage on shares of Guardant Health in a research report on Thursday, April 10th. They set an "outperform" rating and a $55.00 price target for the company. Stifel Nicolaus boosted their target price on shares of Guardant Health from $45.00 to $53.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Scotiabank raised their price target on shares of Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 24th. Finally, JPMorgan Chase & Co. raised their target price on Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Twenty analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $49.00.

Guardant Health Price Performance

NASDAQ GH traded up $3.07 on Wednesday, reaching $46.87. 1,299,780 shares of the company's stock traded hands, compared to its average volume of 2,136,185. The stock has a market cap of $5.78 billion, a PE ratio of -13.17 and a beta of 1.45. Guardant Health, Inc. has a 12 month low of $16.77 and a 12 month high of $50.89. The stock has a 50-day simple moving average of $43.43 and a 200 day simple moving average of $36.76.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. As a group, analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.